摘要
IgA肾病是世界范围内最常见的原发性肾小球疾病,现针对疾病进展高风险IgA肾病尚无公认的标准化治疗方法,临床上多采用对症治疗及联合用药治疗,以达到保护肾功能和延缓疾病进展目的。目前针对IgA肾病的治疗药物仍相对匮乏,生物制剂为IgA肾病治疗提供了新的思路,其不仅减少了长期激素和免疫抑制剂治疗的副作用,并一定程度上改善了IgA肾病患者预后。目前许多生物制剂治疗的临床试验正在进行,本文综述了生物制剂在IgA肾病中的应用及进展,为IgA肾病的治疗提供了参考。
IgA nephropathy is the most common primary glomerular disease in the world.Currently,there is no recognized standardized treatment for IgA nephropathy with high risk of disease progression.Symptomatic treatment and combined drug treatment are commonly used in clinical practice to protect renal function and delay disease progression.At present,the therapeutic drugs for IgA nephropathy are still relatively scarce.Biological agents provide a new idea for IgA nephropathy treatment.The biological agents not only reduce the side effects of long-term glucocorticoids and immunosuppressive therapy,but also improve the prognosis of patients with IgA nephropathy to a certain extent.At present,many clinical trials of biological agents are being carried out.This article reviews the application and progress of biological agents in IgA nephropathy,and provides reference for the treatment of IgA nephropathy.
作者
樊心妍
唐迅子
王畅
刘虹
FAN Xin-yan;TANG Xun-zi;WANG Chang;LIU Hong(Department of Nephropathy,the Second Xiangya Hospital,Central South University,Changsha 410011,China)
出处
《实用医院临床杂志》
2024年第1期31-36,共6页
Practical Journal of Clinical Medicine
基金
国家自然科学基金面上项目(编号:82270752,82070737)
国家自然科学基金青年项目(编号:8190066,82270733)
湖南省自然科学基金面上项目(编号:2021JJ30940)。
作者简介
并列第一作者:樊心妍;并列第一作者:唐迅子;通讯作者:王畅,女,副主任医师,硕士研究生导师。湖南省医学会肾脏病分会血管炎分会副组长。研究方向:IgA肾病和血液净化治疗。
